ArticleWorld journal of diabetes2024

Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.

Jing-Jing Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.